Schizophrenia

CACNA1C genomewide supported psychosis genetic variation affects cortical brain white matter integrity in Chinese patients with schizophrenia.

Woon PS, Sum MY, Kuswanto CN, Yang GL, Sitoh YY, Soong TW, et al. CACNA1C genomewide supported psychosis genetic variation affects cortical brain white matter integrity in Chinese patients with schizophrenia. J Clin Psychiatry. 2014;75(11):e1284-90. DOI: 10.4088/JCP.13m08777. PubMed PMID: 25470093.

Bridging the efficacy-effectiveness gap in the antipsychotic treatment of schizophrenia: back to the basics.

Tandon R. Bridging the efficacy-effectiveness gap in the antipsychotic treatment of schizophrenia: back to the basics. J Clin Psychiatry. 2014;75(11):e1321-2. DOI: 10.4088/JCP.14com09595. PubMed PMID: 25470099.

Recognition of patients who would benefit from LAI antipsychotic treatment: how to assess adherence.

Correll CU. Recognition of patients who would benefit from LAI antipsychotic treatment: how to assess adherence. J Clin Psychiatry. 2014;75(11):e29. DOI: 10.4088/JCP.13024tx3c. PubMed PMID: 25470105.

Schizophrenia: overview and dopamine dysfunction.

Abi-Dargham A. Schizophrenia: overview and dopamine dysfunction. J Clin Psychiatry. 2014;75(11):e31. DOI: 10.4088/JCP.13078tx2c. PubMed PMID: 25470107.

Myotoxicity and neurotoxicity during clozapine treatment.

Reznik I, Volchek L, Mester R, Kotler M, Sarova-Pinhas I, Spivak B, et al. Myotoxicity and neurotoxicity during clozapine treatment. Clin Neuropharmacol. 2000;23(5):276-80. PubMed PMID: 11154096.

The 16p11.2 locus modulates brain structures common to autism, schizophrenia and obesity.

Maillard AM, Ruef A, Pizzagalli F, Migliavacca E, Hippolyte L, Adaszewski S, et al. The 16p11.2 locus modulates brain structures common to autism, schizophrenia and obesity. Mol Psychiatry. 2015;20(1):140-7. DOI: 10.1038/mp.2014.145. PubMed PMID: 25421402.

Treatment resistance and other complicating factors in the management of schizophrenia.

Strassnig MT, Harvey PD. Treatment resistance and other complicating factors in the management of schizophrenia. CNS Spectr. 2014;19 Suppl 1:16-23; quiz 13-5, 24. DOI: 10.1017/S1092852914000571. PubMed PMID: 25410772.

Thinking and acting beyond the positive: the role of the cognitive and negative symptoms in schizophrenia.

Carbon M, Correll CU. Thinking and acting beyond the positive: the role of the cognitive and negative symptoms in schizophrenia. CNS Spectr. 2014;19 Suppl 1:38-52; quiz 35-7, 53. DOI: 10.1017/S1092852914000601. PubMed PMID: 25403863.

The cost of relapse and the predictors of relapse in the treatment of schizophrenia.

Ascher-Svanum H, Zhu B, Faries DE, Salkever D, Slade EP, Peng X, et al. The cost of relapse and the predictors of relapse in the treatment of schizophrenia. Bmc Psychiatry. 2010;10:2. DOI: 10.1186/1471-244X-10-2. PubMed PMID: 20059765; PubMed Central PMCID: PMC2817695.

Factors associated with medication non-adherence in patients suffering from schizophrenia: a cross-sectional study in a universal coverage health-care system.

Dassa D, Boyer L, Benoit M, Bourcet S, Raymondet P, Bottai T. Factors associated with medication non-adherence in patients suffering from schizophrenia: a cross-sectional study in a universal coverage health-care system. Aust N Z J Psychiatry. 2010;44(10):921-8. DOI: 10.3109/00048674.2010.493503. PubMed PMID: 20932206.